Metabolism of arachidonic acid (AA) by cytochrome P450 -hydroxylase leads to the formation of 20-hydroxyeicosatetraenoic acid (20-HETE) that regulates vascular function, sodium homeostasis and blood pressure (BP). Supplementation with n-3 fatty acids is known to alter AA metabolism and reduce formation of the lipid peroxidation products F 2 -isoprostanes, but the effect of n-3 fatty acids on 20-HETE has not been studied. We previously reported a significant effect of n-3 fatty acids but not coenzyme Q10 (CoQ) to reduce BP in a double-blind, placebo-controlled intervention, where patients with chronic kidney disease (CKD) were randomized to n-3 fatty acids (4 g), CoQ (200 mg), both supplements or control (4 g olive oil), daily for 8 weeks. This report examines the effect of n-3 fatty acids on plasma and urinary 20-HETE in the same study, as well as plasma and urinary F 2 -isoprostanes, and relates these to changes in BP. Seventy four patients completed the 8 week intervention. n-3 Fatty acids but not CoQ significantly reduced plasma 20-HETE (P=0.001) and F 2 -isoprostanes (P<0.001).
INTRODUCTION
or to excessive synthesis of renal 20-HETE [5, 6] . In the Dahl salt sensitive rat, reduced renal 20-HETE associates with hypertension [5] , whereas in the spontaneously hypertensive rat, increased renal 20-HETE contributes to raised blood pressure (BP) [6] .
Therefore the effect of 20-HETE on BP depends on the balance of its vasoconstrictor action in the afferent arterioles and its natriuretic actions in the thick ascending loop of Henle.
Supplementation with n-3 fatty acids reduces the formation of arachidonic acid metabolites such as prostaglandins, thromboxane B 2 and leukotriene B 4 [7] , and formation of F 2 -isoprostanes, non-enzymatic free radical oxidation products of arachidonic acid [8, 9] . In addition, n-3 fatty acid supplementation has been shown to reduce BP in a number of randomised controlled trials in humans [10, 11] . However, to date the effect of n-3 fatty acid supplementation on 20-HETE synthesis has not been reported in animal or human studies. Coenzyme Q10 (CoQ) supplementation has also been shown to improve BP [12] and brachial artery endothelial function in type 2 4 diabetes [13] and to enhance the benefit of fenofibrate on the vascular wall [14] We previously reported that n-3 fatty acids but not coenzyme Q10 (CoQ) significantly reduced BP in a double-blind, placebo-controlled intervention, where patients with chronic kidney disease (CKD) were randomized to n-3 fatty acids (n-3 FA) (4 g), CoQ (200 mg), both supplements (n-3 FA+CoQ) or control (4 g olive oil), daily for 8 weeks [15] . This report examines the effect of n-3 fatty acid supplementation on 20-HETE synthesis in patients from that study and relates the changes observed to changes in BP and oxidative stress, as well as urinary nitrate and nitrite as markers of nitric oxide synthesis.
METHODS

Patient Recruitment
Men and women aged 25-75 years, with chronic renal impairment, were recruited from the renal units of Royal Perth, Sir Charles Gairdner and Fremantle Hospitals, in Perth, Western Australia. The patients had an estimated (e)GFR > 15 and < 60 ml/ min/1.73m2 and serum creatinine < 350mmol/l. They were non-smokers and were excluded if they had diabetes; angina pectoris; major surgery, a cardiovascular event or symptoms of cardiovascular disease within the last 3 months; BP > 170/100mmHg; liver disease; nephrotic syndrome (proteinuria >3 g/day or protein/creatinine ratio >300 mg/mmol); or haemoglobin < 110 g/l. Patients were also excluded if they regularly took non-steroidal anti-inflammatory or immunosuppressive drug therapy, nitrates; the phosphodiesterase inhibitor sildenafil; ate more than one fish meal per week or regularly took fish oil supplements; or if they consumed an average of more than four standard alcoholic drinks per day. Antihypertensive or lipid-lowering medication were not exclusion criteria. The study was approved by the ethics committee 5 of Royal Perth Hospital. All patients gave informed written consent. The study was registered with the Australian Clinical Trials Register (ACTRN012605000088640).
Study design
The study was double-blind, placebo-controlled and of 8 weeks duration. During a 3-week familiarization period, patients continued their usual dietary habits. After baseline measurements were obtained, they were stratified by age and BMI, and randomized to one of four study groups: n-3 fatty acids (4 g daily, Omacor, Solvay Urinary 20-HETE was measured by gas chromatography-mass spectrometry (GCMS) using electron capture negative chemical ionization. The assay was a modification of our previously described method [16] and dried under vacuum (6 mm Hg for 2 min) before elution of 20-HETE with hexane/ethyl acetate/acetic acid (75/25/1). The sample was dried and derivatized as previously described for urine [16] .
Plasma and urinary F 2 -isoprostanes were measured using GCMS as previously described [17] .
Urinary nitrite and nitrate were measured from a 24hr urine collection at baseline and the end of the intervention by GCMS as previously described [18] .
Ambulatory Blood pressure monitoring
Ambulatory BP and heart rate (HR) were monitored over 24 hours at baseline and at the end of intervention using the SpaceLabs Monitor (Model 90217, SpaceLabs Medical Inc, Issaquah, Washington, USA) fitted by a trained nurse who instructed the patient in its use. The recorder was pre-set to record BP and HR every 20 min during waking hours and every 30 min during sleep.
Statistical Analysis
The study had more than 80% power to detect main effect changes of 30% in 
RESULTS
Eighty-five patients were randomized to the four groups. Mean values for baseline characteristics were: age 56.5±1.4 years; BMI 27.3±0.5 kg/m 2 ; supine BP was 125.0±1.7/72.3±0.9; eGFR 35.8±1.2 ml/min/1.73m 2 . Seventy-four patients completed the study. Bodyweight and eGFR were similar at baseline in the 4 groups, and did not change significantly during the intervention [15] . Antihypertensive medication was taken by 72 of the 74 patients and did not change throughout the study. At baseline, 74% of patients allocated to n-3 fatty acids were taking angiotensin converting enzyme inhibitors compared with 75% of those allocated to the control oil. Post-intervention levels of platelet total n-3 fatty acids and plasma CoQ confirmed compliance with each of the different treatment regimes. Baseline adjusted, post-intervention platelet total long-chain n-3 fatty acids were significantly elevated in the groups taking n-3 fatty acids (p<0.001): 8.3±0.5% (n-3 FA) and 7.6±0.5% (n-3
FA+CoQ) compared with control and CoQ (4.8±0.5% and 4.9±0.5%, respectively).
Baseline adjusted, post-intervention plasma CoQ was significantly elevated in the groups taking CoQ (p<0.001): 4355±211 nmol/L (CoQ) and 3393±224 nmol/L (n-3
FA+CoQ) compared with 1474±251 nmol/L (control) and 1015±213 nmol/L (n-3 FA).
The Effect of n-3 fatty acids on plasma and urinary 20-HETE and F 2 -isoprostanes, and urinary nitrate and nitrate
There were no significant group differences at baseline. There were no group or interactive effects of CoQ on plasma or urinary 20-HETE, F 2 -isoprostanes (Table 1) .
Therefore, the analysis was confined to the effects of n-3 fatty acid supplementation on plasma and urinary 20-HETE and F 2 -isoprostanes. Figure 1 ).
Urinary 20-HETE and urinary F 2 -isoprostanes were not significantly altered by n-3 fatty acid supplementation (Table 1) .
Urinary nitrite and nitrate excretion was not significantly different between the groups at baseline (Table 2 ). There were no significant group or interactive effects of CoQ on urinary nitrite or nitrate. In a main effects analysis, n-3 fatty acid supplementation for 8 weeks did not significantly alter urinary nitrite or nitrate excretion. Urinary nitrite and nitrate were not significantly correlated with baseline or 
The effect of n-3 fatty acids on the relationship between plasma 20-HETE and BP
Supplementation with n-3 fatty acids significantly reduced BP in this study [15] .
In main effects analysis, n-3 fatty acids reduced 24 h SBP (-3.3±0. The relationship between plasma 20-HETE and BP measured over 24 hr, and while awake or asleep, was examined at baseline and after n-3 fatty acid supplementation using regression analysis. At baseline, after adjusting for age and body 
DISCUSSION
We have shown for the first time that supplementation with n-3 fatty acids for 8 weeks oxide synthase leading to increased oxidative stress and reducing nitric oxide bioavailability 14 . However, we have no evidence of altered NO synthesis in our study as there were no changes in urinary nitrite or nitrate excretion after n-3 fatty acid supplementation. 20-HETE can induce angiotensin converting enzyme and activates the renin angiotensin system thereby further contributing to endothelial dysfunction [20, 21] . A limitation of our study is that we did not assess the effects of n-3 fatty acids on the renin angiotensin system. However, the high proportion of patients in the two groups taking ACE inhibitors (75%) during the study suggests that the renin-angiotensin system was not a major determinant of the relationship between post-intervention 20-HETE and blood pressure. This is supported by the regression analysis which was unaffected when ACE inhibitor status was included in the model. In humans, elevated urinary 20-HETE has been associated with impaired endothelial function [22] , However, we previously reported that in this study there were no changes in endothelial function assessed by flow mediated dilatation after n-3 fatty acids. [15] In hypertensive patients [23] families of -hydroxylases. These enzymes are mainly found in the liver (CYP4A11, 4F2 and 4F3) [24] and kidney (CYP4A11 and 4F2) [25, 26] , but they are also present in human platelets (CYP4A11 and 4F2) [27] , neutrophils (CYP4F3) [28, 29] , smooth muscle cells (CYP4A11) [30] and microvascular endothelial cells (CYP4F2 and 4F3) 13 [21] . A study using human recombinant CYP450 enzymes and human liver microsomes showed that both EPA and DHA strongly inhibited -hydroxylation of arachidonic acid to 20-HETE by CYP4F2 and CYP4F3B [31] , the two main CYP4
enzymes involved in -hydroxylation in the liver. We previously reported significant increases in both EPA and DHA in platelets in this study after n-3 fatty acid supplementation [15] , that are likely to reflect changes in fatty acid composition in the liver and other tissues. In this study n-3 fatty acid supplementation may have led to We found no effect on urinary 20-HETE levels after supplementation with n-3 fatty acids. In humans, the majority of 20-HETE is excreted as the glucuronide conjugate [32] . Glucuronidation is a metabolic process involved in phase II drug metabolism and is important for clearance of 20-HETE from the circulation in humans.
It occurs mainly in the liver but can take place in all major organs including the kidney.
The assay used to measure urinary 20-HETE in this study treats urine with glucuronidase to enable measurement of total 20-HETE excretion [33] . In contrast measurement of 20-HETE in plasma represents free 20-HETE. It is possible that renal impairment affects renal synthesis and/or clearance of 20-HETE from the circulation masking any effect of n-3 fatty acids on urinary 20-HETE in patients with CKD.
Only one other study has examined CYP450 eicosanoids in relation to renal disease in humans [34] . In that study, plasma and urinary 20-HETE were measured in patients with renovascular disease (diagnosed by angiographic evidence of severe renal 14 artery stenosis), essential hypertension and healthy controls. The study showed that plasma 20-HETE was elevated and urinary 20-HETE was reduced in renovascular disease compared with controls. This suggests that plasma and urinary 20-HETE are also differentially affected in human renovascular disease.
In this study n-3 fatty acids reduced plasma but not urinary F 2 -isoprostanes. We have previously shown that n-3 fatty acids reduce both plasma and urinary F 2 -isoprostanes [35] [36] [37] [38] in patients with normal renal function. The absence of changes in urinary F 2 -isoprostanes after n-3 fatty acids may be related to the renal impairment in CKD.
We have previously reported that n-3 fatty acid supplementation in these CKD patients did not affect renal function [15] . We found no significant relationship between plasma or urinary 20-HETE or F 2 -isoprostanes and renal function (eGFR) at baseline or after the intervention. Limitations in our trial include the small sample size studied and the relatively short duration of n-3 fatty acid supplementation that may have impacted on our ability to determine any effect of n-3 fatty acids and reduced plasma 20-HETE on renal function.
In conclusion, we have shown for the first time that n-3 fatty acid supplementation in patients with CKD significantly reduces plasma 20-HETE and that this reduction is significantly associated with reduced BP. These results suggest that a reduction in 20-HETE may be a plausible mechanism for the reduction in BP observed in patients with CKD following n-3 fatty acid supplementation. 
